Skip to main content
DeutschDE
European Commission logo print header

Cell-Based Models for Neurodegeneration Study and Use in Screening

Ziel

1. Treatment of neurodegenerative disease is an unmet clinical challenge and patient care is a growing, unsustainable global healthcare burden. The project will produce novel tools to address this challenge.
2. The consortium will deliver a set of innovative analytical tools for neurodegenerative drug discovery using a combination of stem cell biology and novel biomaterials assembled by additive manufacturing.
3. The toolset will be analytical kits containing induced pluripotent stem cell (iPSC)-derived human neural cells in 3D culture formats, delivered to end-users in multiwell plates ready for industrial screening.
4. Project outputs will be realised by an inter-disciplinary consortium of four SME commercial partners in three European countries, each partner supplying a specific, essential skillset.
5. iPSC-derived neural cells will be produced by Phenocell sarl (F) using stem cell differentiation protocols already shown to generate glial or neuronal cell lineages, and to reinstate donor disease phenotypes.
6. Bio-printer instrumentation and printable bio-inks to manufacture 3D scaffolds enabling 3D cell culture will be contributed by Cellink (SE).
7. 3D culture models will be customised for neural/neurodegenerative cell culture by inclusion of peptide dendrons with biological functionality using mature chemistry proprietary to Tissue Click Ltd (UK).
8. Cell-based analysis products will be validated, and made user-friendly by in situ cell cryopreservation and analytical processes familiar to AvantiCell Science Ltd (UK).
9. Each contributing technology is at TRL 6, and each has commercial utility in simpler combinations. The project assembles them in first-to-market formats beyond the current state of the art.
10. The CENSUS project output, comprising iPSC-derived neural cells cryopreserved in single-cell and co-culture 3D formats will deliver exceptional analytical precision and predictive value, unprecedented end-user convenience and strong commercial advantage

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

H2020-FTIPilot-2016

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-FTIPilot-2016-1

Finanzierungsplan

IA - Innovation action

Koordinator

AvantiCell Science Ltd
Netto-EU-Beitrag
€ 675 736,25
Adresse
GIBBSYARD BUILDING
KA6 5HW Ayr
Vereinigtes Königreich

Auf der Karte ansehen
KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).
Ja
Region
Scotland Southern Scotland South Ayrshire
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 965 337,50

Beteiligte (3)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 16 August 2022

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/730678/de

European Union, 2024